Physical priors improve performance of structure-based binding affinity models
Structure-based drug discovery is a widely used paradigm for the rational design of novel small molecule therapeutics. However, the benefits conferred by the use of structural information has seen limited adoption in machine learning, where ligand-only ("2D") models are still the industry standard for molecular property or binding affinity prediction. Structure-based ("3D") ML models for…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
